Ficlatuzumab: Difference between revisions
Content deleted Content added
m Task 18 (cosmetic): eval 2 templates: hyphenate params (1×); |
added MoA |
||
| Line 43: | Line 43: | ||
'''Ficlatuzumab''' is a humanized monoclonal antibody designed for the treatment of cancers.<ref>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Ficlatuzumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/ficlatuzumab.pdf}}</ref> |
'''Ficlatuzumab''' is a humanized monoclonal antibody designed for the treatment of cancers.<ref>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Ficlatuzumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/ficlatuzumab.pdf}}</ref> |
||
It is a humanized monoclonal antibody that binds to [[hepatocyte growth factor]], thus inhibiting the [[c-MET]] receptor signaling cascade.<ref name="pmid33725344">{{cite journal | vauthors = Panahi Y, Mohammadzadeh AH, Behnam B, Orafai HM, Jamialahmadi T, Sahebkar A | title = A Review of Monoclonal Antibody-Based Treatments in Non-small Cell Lung Cancer | journal = Advances in Experimental Medicine and Biology | volume = 1286 | issue = | pages = 49–64 (57) | date = 2021 | pmid = 33725344 | doi = 10.1007/978-3-030-55035-6_3 }}</ref> |
|||
Ficlatuzumab was developed by AVEO Pharmaceuticals. In May 2012, AVEO released results of a Phase II clinical trial comparing [[gefitinib]] alone and in combination with ficlatuzamab in treatment-naive Asian patients with [[non-small cell lung cancer]].<ref>{{Citation |date=May 3, 2012 |title=AVEO Releases Phase 2 Data |periodical=[[Drug Discovery & Development]] |at=dddmag.com |url=http://www.dddmag.com/news/2012/05/aveo-releases-phase-2-data |access-date=June 3, 2012 }}</ref> |
Ficlatuzumab was developed by AVEO Pharmaceuticals. In May 2012, AVEO released results of a Phase II clinical trial comparing [[gefitinib]] alone and in combination with ficlatuzamab in treatment-naive Asian patients with [[non-small cell lung cancer]].<ref>{{Citation |date=May 3, 2012 |title=AVEO Releases Phase 2 Data |periodical=[[Drug Discovery & Development]] |at=dddmag.com |url=http://www.dddmag.com/news/2012/05/aveo-releases-phase-2-data |access-date=June 3, 2012 }}</ref> |
||
Revision as of 12:25, 5 November 2022
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Humanized (from mouse) |
| Target | HGF |
| Clinical data | |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C6446H9954N1718O2026S46 |
| Molar mass | 145409.30 g·mol−1 |
  (what is this?) (verify) | |
Ficlatuzumab is a humanized monoclonal antibody designed for the treatment of cancers.[1]
It is a humanized monoclonal antibody that binds to hepatocyte growth factor, thus inhibiting the c-MET receptor signaling cascade.[2]
Ficlatuzumab was developed by AVEO Pharmaceuticals. In May 2012, AVEO released results of a Phase II clinical trial comparing gefitinib alone and in combination with ficlatuzamab in treatment-naive Asian patients with non-small cell lung cancer.[3]
References
- ^ "Statement On A Nonproprietary Name Adopted By The USAN Council: Ficlatuzumab" (PDF). American Medical Association.
- ^ Panahi Y, Mohammadzadeh AH, Behnam B, Orafai HM, Jamialahmadi T, Sahebkar A (2021). "A Review of Monoclonal Antibody-Based Treatments in Non-small Cell Lung Cancer". Advances in Experimental Medicine and Biology. 1286: 49–64 (57). doi:10.1007/978-3-030-55035-6_3. PMID 33725344.
- ^ "AVEO Releases Phase 2 Data", Drug Discovery & Development, dddmag.com, May 3, 2012, retrieved June 3, 2012
 | This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |
 | This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it. |